Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Head of R&D, CSO

Chief Tech Ops Officer

EVP, General Counsel

Chief Financial Officer

President & CEO

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; and AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program that is under Phase 1/2a clinical trial; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Selecta Biosciences; Hansa Biopharma; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therape...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-03-11	Premium	sold	Premium	Premium	Premium	-
2024-03-08	Premium	sold (taxes)	Premium	Premium	Premium	Head of R&D, CSO
2024-03-08	Premium	sold	Premium	Premium	Premium	-
2024-03-08	Premium	sold (taxes)	Premium	Premium	Premium	Chief Tech Ops Officer
2024-03-08	Premium	sold (taxes)	Premium	Premium	Premium	EVP, General Counsel
2024-03-08	Premium	acquired	Premium	Premium	Premium	-
2024-03-08	Premium	sold (taxes)	Premium	Premium	Premium	Chief Financial Officer
2024-03-07	Premium	sold (taxes)	Premium	Premium	Premium	Head of R&D, CSO
2024-03-07	Premium	sold (taxes)	Premium	Premium	Premium	EVP, General Counsel
2024-03-07	Premium	sold (taxes)	Premium	Premium	Premium	Chief Tech Ops Officer
2024-03-07	Premium	sold (taxes)	Premium	Premium	Premium	Chief Financial Officer
2024-03-05	Premium	sold	Premium	Premium	Premium	-
2024-03-04	Premium	sold (taxes)	Premium	Premium	Premium	Head of R&D, CSO
2024-03-04	Premium	sold (taxes)	Premium	Premium	Premium	Chief Tech Ops Officer
2024-03-04	Premium	sold (taxes)	Premium	Premium	Premium	EVP, General Counsel
2024-03-04	Premium	sold (taxes)	Premium	Premium	Premium	Chief Financial Officer
2024-03-01	Premium	acquired	Premium	Premium	Premium	-
2024-03-01	Premium	sold	Premium	Premium	Premium	EVP, General Counsel
2024-03-01	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2024-03-01	Premium	sold (taxes)	Premium	Premium	Premium	Chief Financial Officer
2024-03-01	Premium	acquired	Premium	Premium	Premium	-
2024-03-01	Premium	acquired	Premium	Premium	Premium	Head of R&D, CSO
2024-03-01	Premium	acquired	Premium	Premium	Premium	-
2024-03-01	Premium	sold (taxes)	Premium	Premium	Premium	Chief Tech Ops Officer
2024-03-01	Premium	acquired	Premium	Premium	Premium	-

SRPT - Sarepta Therapeutics Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for SRPT